ArticleFrontiers in genetics2025
Validation of a comprehensive long-read sequencing platform for broad clinical genetic diagnosis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Intra-amniotic infection: diagnosis, nomenclature, clinical significance, management, and microbiologic tools used for the diagnosis.Clinical microbiology reviews · 2026Review
- Benchmarking long-read variant sensitivity across ONT and PacBio platforms using known clinically reported variants in a cohort of critically ill newborns.medRxiv : the preprint server for health sciences · 2026Article
- Comparative Evaluation of Sequencing Technologies for Detecting Antimicrobial Resistance in Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Long-Read Sequencing and Structural Variant Detection: Unlocking the Hidden Genome in Rare Genetic Disorders.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though short read high-throughput sequencing, commonly known as Next-Generation Sequencing (NGS), has revolutionized genomics and genetic testing, there is no single genetic test that can accurately detect single nucleotide variants (SNVs), small insertions/deletions (indels), complex structural variants (SVs), repetitive genomic alterations, and variants in genes with highly homologous pseudogenes. The implementation of a unified comprehensive technique that can simultaneously detect a broad spectrum of genetic variation would substantially increase efficiency of the diagnostic process. The current study evaluated the clinical utility of long-read sequencing as a comprehensive genetic test for diagnosis of inherited conditions. Using Oxford Nanopore Technologies long read nanopore sequencing, we successfully developed and validated a clinically deployable integrated bioinformatics pipeline that utilizes a combination of eight publicly available variant callers. A concordance assessment comparing the known variant calls from a well-characterized, benchmarked sample called NA12878 from the National Institute of Standards and Technology (NIST) with the variants detected by our pipeline for this sample, determined that the analytical sensitivity of our pipeline was 98.87% and the analytical specificity exceeded 99.99%. We then evaluated our pipeline's ability to detect 167 clinically relevant variants from 72 clinical samples. This set of variants consisted of 80 SNVs, 26 indels, 32 SVs, and 29 repeat expansions, including 14 variants in genes with highly homologous pseudogenes. The overall detection concordance for these clinically relevant variants was 99.4% (95% CI: 99.7%-99.9%). Importantly, in addition to detecting known clinically relevant variants, in four cases, our pipeline yielded valuable additional information in support of clinical diagnoses that could not have been established using short-read NGS alone. Our findings suggest that long-read sequencing is successful in identifying diverse genomic alterations and that our pipeline functions well as the basis for a single diagnostic test for patients with suspected genetic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.